Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Karyopharm Therapeutics (KPTI) over the last 13 years, with Q4 2025 value amounting to -$72.6 million.

  • Karyopharm Therapeutics' Other Non Operating Income changed N/A to -$72.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$62.4 million, marking a year-over-year decrease of 22808.58%. This contributed to the annual value of -$62.4 million for FY2025, which is 23951.28% down from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Other Non Operating Income stood at -$72.6 million.
  • In the past 5 years, Karyopharm Therapeutics' Other Non Operating Income ranged from a high of $44.7 million in Q2 2024 and a low of -$72.6 million during Q4 2025
  • In the last 5 years, Karyopharm Therapeutics' Other Non Operating Income had a median value of -$13000.0 in 2022 and averaged -$747315.8.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Other Non Operating Income tumbled by 152307.69% in 2023, and later skyrocketed by 14890666.67% in 2024.
  • Over the past 5 years, Karyopharm Therapeutics' Other Non Operating Income (Quarter) stood at -$478000.0 in 2021, then skyrocketed by 97.28% to -$13000.0 in 2022, then tumbled by 1523.08% to -$211000.0 in 2023, then skyrocketed by 1897.16% to $3.8 million in 2024, then tumbled by 2013.53% to -$72.6 million in 2025.
  • Its Other Non Operating Income stands at -$72.6 million for Q4 2025, versus -$7.4 million for Q3 2025 and -$2.2 million for Q2 2025.